McKesson's prospects are being driven by robust growth in specialty distribution, oncology services and biopharma solutions, though persistent margin pressures and volatility across certain segments remain concerns. In the fiscal fourth quarter, the oncology and multispecialty segment delivered 35% revenue growth and 53% operating profit growth, while the North American Pharmaceutical segment's operating profit increased 11% to $980 million, supported by continued specialty drug demand and GLP-1 therapy momentum. However, management disclosed that price reductions by branded manufacturers lowered North American Pharmaceutical revenue growth by approximately 3 percentage points during the quarter, and similar headwinds are expected throughout fiscal 2027. Additionally, the Prescription Technology Solutions business, which saw 12% revenue growth and 13% operating profit growth, faces non-linear and unpredictable future performance, with fiscal 2027 revenue growth guided at only 2.5-6.5%. McKesson's acquisition-led growth strategy also increases integration risk, as acquisitions accounted for approximately 34% of operating profit growth in the oncology segment in fiscal 2026.
McKesson CorporationPrice reductions by branded manufacturers lowered revenue growth by ~3pp and are expected to continue through fiscal 2027
Globus Medical
West Pharmaceutical Services Inc